This company has been marked as potentially delisted and may not be actively trading. XTL Biopharmaceuticals (XTLB) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrendsBuy This Stock XTLB vs. IVCP, JATT, BTAI, HSAQ, DYAI, KZR, CVKD, MIRA, TENX, and CASIShould you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include Swiftmerge Acquisition (IVCP), JATT Acquisition (JATT), BioXcel Therapeutics (BTAI), Health Sciences Acquisitions Co. 2 (HSAQ), Dyadic International (DYAI), Kezar Life Sciences (KZR), Cadrenal Therapeutics (CVKD), MIRA Pharmaceuticals (MIRA), Tenax Therapeutics (TENX), and CASI Pharmaceuticals (CASI). These companies are all part of the "medical" sector. XTL Biopharmaceuticals vs. Its Competitors Swiftmerge Acquisition JATT Acquisition BioXcel Therapeutics Health Sciences Acquisitions Co. 2 Dyadic International Kezar Life Sciences Cadrenal Therapeutics MIRA Pharmaceuticals Tenax Therapeutics CASI Pharmaceuticals Swiftmerge Acquisition (NASDAQ:IVCP) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment. Is IVCP or XTLB more profitable? XTL Biopharmaceuticals' return on equity of 0.00% beat Swiftmerge Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Swiftmerge AcquisitionN/A -11.71% -0.23% XTL Biopharmaceuticals N/A N/A N/A Which has more volatility & risk, IVCP or XTLB? Swiftmerge Acquisition has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Do insiders & institutionals hold more shares of IVCP or XTLB? 38.1% of Swiftmerge Acquisition shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 42.9% of Swiftmerge Acquisition shares are owned by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher earnings and valuation, IVCP or XTLB? Swiftmerge Acquisition has higher earnings, but lower revenue than XTL Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSwiftmerge AcquisitionN/AN/A$3.42M-$0.02-206.00XTL Biopharmaceuticals$450K14.05-$1.03MN/AN/A Does the media favor IVCP or XTLB? In the previous week, Swiftmerge Acquisition's average media sentiment score of 0.00 equaled XTL Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Swiftmerge Acquisition Neutral XTL Biopharmaceuticals Neutral SummaryXTL Biopharmaceuticals beats Swiftmerge Acquisition on 4 of the 7 factors compared between the two stocks. Get XTL Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XTLB vs. The Competition Export to ExcelMetricXTL BiopharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.40M$415.98M$5.82B$9.76BDividend YieldN/A2.45%4.40%4.04%P/E RatioN/A7.2122.5724.55Price / Sales14.053.36472.41122.43Price / CashN/A8.4125.7828.78Price / Book1.160.899.526.07Net Income-$1.03M$10.55M$3.26B$265.39M XTL Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XTLBXTL BiopharmaceuticalsN/A$1.16+2.7%N/AN/A$6.40M$450K0.00N/AIVCPSwiftmerge AcquisitionN/A$4.40+3.7%N/A-62.6%$30.08MN/A-219.882,021Gap UpJATTJATT AcquisitionN/A$1.74+4.8%N/A-43.7%$30.02MN/A0.003High Trading VolumeBTAIBioXcel Therapeutics4.5666 of 5 stars$4.90-13.6%$39.75+711.6%-54.2%$29.50M$2.27M-0.3990Short Interest ↓HSAQHealth Sciences Acquisitions Co. 2N/A$2.63+2.5%N/A-58.7%$29.49MN/A0.004News CoverageDYAIDyadic International2.7743 of 5 stars$0.81+1.5%$6.00+643.5%-41.4%$29.21M$3.49M-4.257Gap UpKZRKezar Life Sciences3.8628 of 5 stars$3.90+1.0%$9.00+130.8%-35.4%$28.55M$7M-0.4060High Trading VolumeCVKDCadrenal Therapeutics3.0022 of 5 stars$13.71+5.0%$32.00+133.5%+69.6%$28.10MN/A-1.544MIRAMIRA Pharmaceuticals3.0251 of 5 stars$1.43-3.7%$17.00+1,093.0%-22.7%$27.18MN/A-2.912Analyst UpgradeTENXTenax Therapeutics1.6107 of 5 stars$5.95-1.0%$17.00+185.7%+42.2%$27.13MN/A-6.479CASICASI Pharmaceuticals3.709 of 5 stars$2.19-3.3%$4.00+83.0%-63.4%$26.89M$28.54M-0.86180Gap Down Related Companies and Tools Related Companies Swiftmerge Acquisition Competitors JATT Acquisition Competitors BioXcel Therapeutics Competitors Health Sciences Acquisitions Co. 2 Competitors Dyadic International Competitors Kezar Life Sciences Competitors Cadrenal Therapeutics Competitors MIRA Pharmaceuticals Competitors Tenax Therapeutics Competitors CASI Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XTLB) was last updated on 8/24/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access